30 completed, 18 recruiting, 12 unknown, 9 terminated. 78 Phase 2, 22 Phase 1, 8 Phase 3.
Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers L608, Placebo - Systemic Sclerosis | Phase 2 | Not yet recruiting | Pharmosa Biopharm Inc. | 40 | 2027-02-01 | 2026-11-09 |
| A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further. ABBV-722, Upadacitinib, Placebo for ABBV-722 - Systemic Sclerosis | Phase 2 / Phase 3 | Not yet recruiting | AbbVie | 580 | 2026-12-11 | 2026-11-12 |
| Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma hyaluronidase - Scleroderma, Sclerodactyly | Phase 2 | Not yet recruiting | Stanford University | 10 | 2026-12-01 | 2026-11-06 |
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis Hyperpolarized 129 Xenon Gas - Interstitial Lung Disease, Pulmonary Hypertension | Phase 2 | Not yet recruiting | Bastiaan Driehuys | 51 | 2026-11-01 | 2026-09-15 |
| Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis 10 mg/kg CM-101, Placebo - Systemic Sclerosis | Phase 2 | Suspended | ChemomAb Ltd. | 45 | 2026-09-01 | 2026-04-15 |
| Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. umbilical cord blood CD19-BCMA CAR-T cells infusion - Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 45 | 2026-03-18 | 2026-03-03 |
| Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases Depletion of CD3/CD19 in an autologous stem cell transplant - Systemic Lupus Erythematosus, Systemic Sclerosis | Phase 2 | Recruiting | Stephan Grupp MD PhD | 20 | 2026-03-01 | 2025-10-14 |
| A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis Nemolizumab, Placebo - Systemic Sclerosis | Phase 2 | Recruiting | Galderma R&D | 162 | 2026-02-20 | 2026-03-31 |
| A Study of AZD0120 in Autoimmune Diseases AZD0120, SOC - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 27 | 2026-01-09 | 2026-11-10 |
| CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH CD19-BCMA CAR-T cells infusion - Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 45 | 2025-04-18 | 2026-07-30 |
| Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases Mesenchymal Stem Cells, Placebo - Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 200 | 2025-02-01 | 2025-03-21 |
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NKX019, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | Nkarta, Inc. | 240 | 2024-11-04 | 2026-10-30 |
| Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease Mycophenolate Mofetil, Placebo - Systemic Sclerosis With Lung Involvement, Systemic Sclerosis | Phase 2 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 35 | 2024-08-29 | 2026-09-29 |
| KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis KYV-101, Standard lymphodepletion regimen - Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 3 | 2024-08-06 | 2026-08-31 |
| Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders Tafasitamab, Fludarabine phosphate, Cyclophosphamide - Autoimmune Disorders, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 47 | 2024-07-31 | 2026-11-03 |
| Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) CD19- BCMA CAR-T cells - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2024-10-15 |
| RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis CABA-201 - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Recruiting | Cabaletta Bio | 37 | 2024-07-02 | 2026-10-16 |
| Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis Topical 25% sodium metabisulfite (SM) in pediatric cold cream, Placebo - Systemic Sclerosis, Calcinosis | Phase 1 / Phase 2 | Unknown | Pontificia Universidad Catolica de Chile | 20 | 2024-01-02 | 2023-12-04 |
| RY_SW01 Cell Injection Therapy in Systemic Sclerosis RY_SW01 cell injection, Basic treatment - Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Jiangsu Renocell Biotech Company | 81 | 2023-09-22 | 2024-01-18 |
Showing 20 of 78. Sign in to see all of them.
Scleroderma, Systemic (78) · Scleroderma, Diffuse (26) · Lung Diseases, Interstitial (9) · Lupus Erythematosus, Systemic (8) · Arthritis, Rheumatoid (6) · Autoimmune Diseases (5) · digital ulcers (5) · Hypertension, Pulmonary (4) · Lupus Nephritis (4) · Myositis (4) · Arthritis (3) · Dermatomyositis (3) · Raynaud Disease (3) · Scleroderma, Limited (3) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2)
Skin Diseases (78) · Skin and Connective Tissue Diseases (78) · Connective Tissue Diseases (76) · Lung Diseases (15) · Respiratory Tract Diseases (15) · Immune System Diseases (14) · Cardiovascular Diseases (13) · Musculoskeletal Diseases (12) · Vascular Diseases (11) · Joint Diseases (10) · Autoimmune Diseases (9) · Pathological Conditions, Signs and Symptoms (9) · Arthritis (7) · Muscular Diseases (7) · Nervous System Diseases (7)
Cyclophosphamide (6) · Mycophenolic Acid (5) · Rituximab (4) · Antilymphocyte Serum (3) · Imatinib Mesylate (3) · fludarabine (3) · treprostinil (3) · Filgrastim (2) · GLPG1690 (2) · Immunoglobulins, Intravenous (2) · Mesna (2) · Saline Solution (2) · Sirolimus (2) · belimumab (2) · fludarabine phosphate (2)
Hospital for Special Surgery, New York (4) · Assistance Publique - Hôpitaux de Paris (3) · Beijing GoBroad Hospital (2) · Heidelberg University (2) · Lakefront Biotherapeutics NV (2) · Northwestern University (2) · Sanofi (2) · Stanford University (2) · United Therapeutics (2) · University College, London (2) · University of California, Los Angeles (2) · AbbVie (1) · Active Biotech AB (1) · Assistance Publique Hopitaux De Marseille (1) · AstraZeneca (1)
United States (35) · United Kingdom (15) · France (11) · Germany (10) · Italy (9) · China (6) · Canada (5) · Switzerland (5) · Belgium (4) · Spain (4) · Poland (3) · Australia (2) · Mexico (2) · Netherlands (2) · Russia (2)
Robert Spiera, MD (4) · James Seibold, MD (2) · Andrei Hancharou, Dr (1) · Anna-Maria Hoffmann-Vold, MD, PhD (1) · Antonia Valenzuela, MD, MS (1) · Ariane Herrick, MD (1) · Armando Gabrielli, MD (1) · Ayumi Yoshizaki, MD, PhD (1) · Benjamin Chaigne, MD (1) · Brett King, MD, PhD (1)
PMID 28298564, PMID 18634152, PMID 19950289, PMID 21398330, PMID 21769849, PMID 22542159, PMID 24067785, PMID 25007944, PMID 26283632, PMID 27370878, PMID 28270187, PMID 28724445, PMID 29073351, PMID 29732731, PMID 30127049, PMID 30277862, PMID 30472651, PMID 31208714, PMID 31655622, PMID 31858338, PMID 32612255, PMID 32963047, PMID 34168032, PMID 34330322, PMID 34718447, PMID 35894657, PMID 35943798, PMID 36637209, PMID 38206544, PMID 39900089, PMID 41501497, PMID 42177178, PMID 42309868, PMID 42457022
2019 (5), 2014 (1), 2015 (1), 2016 (1), 2018 (1), R01AR047219 (1), R01HL126771 (1), R34HL122558 (1)